RÉSUMÉ
Epstein-Barr virus (EBV) is a ubiquitous and predominantly B cell tropic virus. One of the most common viruses to infect humans, EBV, is best known as the causative agent of infectious mononucleosis (IM). Although most people experience asymptomatic infection, EBV is a potent immune stimulus and as such it elicits robust proliferation and activation of the B-lymphocytes it infects as well as the immune cells that respond to infection. In certain individuals, such as those with inherited or acquired defects affecting the immune system, failure to properly control EBV leads to the accumulation of EBV-infected B cells and EBV-reactive immune cells, which together contribute to the development of often life-threatening cytokine storm syndromes (CSS). Here, we review the normal immune response to EBV and discuss several CSS associated with EBV, such as chronic active EBV infection, hemophagocytic lymphohistiocytosis, and post-transplant lymphoproliferative disorder. Given the critical role for cytokines in driving inflammation and contributing to disease pathogenesis, we also discuss how targeting specific cytokines provides a rational and potentially less toxic treatment for EBV-driven CSS.
Sujet(s)
Syndrome de libération de cytokines , Cytokines , Infections à virus Epstein-Barr , Herpèsvirus humain de type 4 , Humains , Syndrome de libération de cytokines/immunologie , Syndrome de libération de cytokines/virologie , Herpèsvirus humain de type 4/immunologie , Infections à virus Epstein-Barr/immunologie , Infections à virus Epstein-Barr/virologie , Infections à virus Epstein-Barr/complications , Cytokines/immunologie , Cytokines/métabolisme , Lymphohistiocytose hémophagocytaire/immunologie , Lymphohistiocytose hémophagocytaire/virologie , Lymphocytes B/immunologie , Lymphocytes B/virologie , Syndromes lymphoprolifératifs/immunologie , Syndromes lymphoprolifératifs/virologie , AnimauxRÉSUMÉ
A wide variety of infections can trigger cytokine storm syndromes including those caused by bacteria, viruses, fungi and parasites. The most frequent viral trigger is Epstein-.Barr virus which is covered in Chapter 16. CSS associated with COVID-19 is also discussed separately (Chapter 22). This chapter will focus on other viruses including the hemorrhagic fever viruses, influenza, parainfluenza, adenovirus, parvovirus, hepatitis viruses, measles, mumps, rubella, enterovirus, parechovirus, rotavirus, human metapneumovirus and human T-lymphotropic virus. The published literature consists of many single case reports and moderate-sized case series reporting CSS, in most circumstances meeting the 2004 diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH). There is no published clinical trial evidence specifically for management of HLH associated with these viruses. In some situations, patients received supportive therapy and blood product transfusions only but in most cases, they were treated with one or more of intravenous corticosteroids, intravenous immunoglobulin and/or etoposide. These were successful in many patients although in significant numbers progression of infection to CSS was associated with mortality.
Sujet(s)
COVID-19 , Syndrome de libération de cytokines , Humains , Syndrome de libération de cytokines/immunologie , COVID-19/complications , COVID-19/immunologie , COVID-19/thérapie , COVID-19/virologie , Lymphohistiocytose hémophagocytaire/thérapie , Lymphohistiocytose hémophagocytaire/immunologie , Lymphohistiocytose hémophagocytaire/virologie , SARS-CoV-2 , Fièvres hémorragiques virales/virologieRÉSUMÉ
BACKGROUND: Epstein-Barr virus DNA (EBV-DNA) is closely related to the pathogenesis and prognosis of EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). The quantitative measurement of blood EBV-DNA is widely used in EBV-HLH, but there remains a lack of evidence to guide clinicians. METHODS: A retrospective analysis was conducted on clinical manifestations, laboratory tests, 310 blood EBV-DNA loads, and prognosis of 51 pediatric patients diagnosed with EBV-HLH. Receiver operating characteristic (ROC) curves were utilized to determine the optimal cutoff values of EBV-DNA for predicting mortality and evaluating the active status of EBV-HLH. RESULTS: EBV-positive- lymphoma-HLH had higher initial plasma EBV-DNA load(1.10 × 106copies/ml) compared to the EBV-HLH group (1.98 × 104 copies/ml) (P = 0.006), and experienced recurrently elevated plasma EBV-DNA levels during treatment. The optimal cut-off value of initial plasma EBV-DNA load in predicting mortality was 2.68 × 105 copies/ml, with a sensitivity of 88.57% and a specificity of 56.25%. For determining the active status of HLH, the optimal cutoff value of PBMC EBV-DNA load during treatment was 2.95 × 105 copies/ml, with a sensitivity of 69.14% and a specificity of 64.71%. The cut-off value of plasma EBV-DNA for determining active status was 1.32 × 103 copies/ml, with a sensitivity of 84.34%, and a specificity of 87.67%. Patients with higher PBMC and plasma EBV-DNA at initial and those with repeated elevated plasma EBV-DNA during treatment had worse prognoses (P < 0.05). CONCLUSION: Dynamic monitoring of EBV-DNA is a valuable tool for assessing disease status and predicting the prognosis of EBV-HLH, with plasma EBV-DNA being more effective than PBMC EBV-DNA. Patients with high levels of PBMC and plasma EBV-DNA at initial and those with repeated elevated plasma EBV-DNA during treatment had worse prognoses.
Sujet(s)
ADN viral , Infections à virus Epstein-Barr , Herpèsvirus humain de type 4 , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/sang , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/virologie , Études rétrospectives , Mâle , Femelle , ADN viral/sang , Enfant , Enfant d'âge préscolaire , Infections à virus Epstein-Barr/sang , Infections à virus Epstein-Barr/diagnostic , Infections à virus Epstein-Barr/complications , Herpèsvirus humain de type 4/génétique , Chine , Pronostic , Nourrisson , Charge virale , Adolescent , Peuples d'Asie de l'EstRÉSUMÉ
Anti-interferon-γ monoclonal antibody emapalumab and JAK1/2 inhibitors ruxolitinib have been widely reported for the treatment of hemophagocytic lymphohistiocytosis (HLH) recently. These targeted drugs have fewer side effects and may provide new options for patients with HLH who are refractory to previous treatment or intolerant to chemotherapy. Herein, we reported a case of Epstein-Barr virus-related HLH, which did not respond well to HLH-94 plus ruxolitinib and developed severe fungal infection. The disease was successfully controlled after a combination therapy of emapalumab, ruxolitinib, and dexamethasone.
Sujet(s)
Anticorps monoclonaux , Dexaméthasone , Infections à virus Epstein-Barr , Lymphohistiocytose hémophagocytaire , Nitriles , Pyrazoles , Pyrimidines , Humains , Lymphohistiocytose hémophagocytaire/traitement médicamenteux , Lymphohistiocytose hémophagocytaire/étiologie , Lymphohistiocytose hémophagocytaire/virologie , Pyrazoles/usage thérapeutique , Pyrimidines/usage thérapeutique , Infections à virus Epstein-Barr/complications , Infections à virus Epstein-Barr/traitement médicamenteux , Dexaméthasone/usage thérapeutique , Dexaméthasone/administration et posologie , Anticorps monoclonaux/usage thérapeutique , Association de médicaments , Mâle , Herpèsvirus humain de type 4 , Femelle , Anticorps neutralisantsRÉSUMÉ
Haemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disorder caused by uncontrolled activation of the immune system, leading to phagocytosis of blood cells and cytokine storm. HLH can manifest in childhood due to a genetic mutation, but in adults HLH arises secondary to viral infections, autoimmune diseases or neoplastic processes. The most common viral infections associated with HLH are Epstein-Barr virus (EBV) and cytomegalovirus (CMV). EBV and CMV coinfection associated with HLH, however, is exceedingly rare. We present a case of HLH secondary to EBV and CMV coinfection in a young adult who presented with recurrent intermittent high-grade fevers and epistaxis. This case illustrates the importance of considering HLH in patients with idiopathic fevers and to consider all the potential aetiologies for HLH to ensure proper treatment.
Sujet(s)
Co-infection , Infections à cytomégalovirus , Infections à virus Epstein-Barr , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/étiologie , Infections à virus Epstein-Barr/complications , Infections à virus Epstein-Barr/diagnostic , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/diagnostic , Mâle , Herpèsvirus humain de type 4 , Antiviraux/usage thérapeutique , Cytomegalovirus , AdulteRÉSUMÉ
BACKGROUND: The goal was to study the difference of virological, immunologic, and inflammatory indicators between Epstein-Barr associated infectious mononucleosis (EBV-IM) and EBV associated hemophagocytic lymphohistiocytosis (EBV-HLH) and to explore the evaluation indicators for monitoring the therapeutic efficacy of EBV-HLH. METHODS: Twenty children with EBV-IM (IM group) and 10 children with EBV-HLH (HLH group) were selected. Virology indicators were detected; the absolute count of lymphocyte, and lymphocyte subsets were detected; the levels of immunoglobulin and ferritin were assayed. RESULTS: Compared to the IM group, the HLH group showed a decrease in EBV-specific VCA-IgM antibody levels (U = 29.0, p = 0.006) and an increase in EBV-specific NA-IgG antibody levels (U = 17.0, p = 0.001), while there was no significant difference in EB-DNA loads (t = 0.417, p = 0.680). The counts of lymphocytes, and various lymphocyte subsets in the HLH group were lower than those in the IM group. Inflammatory markers in the HLH group were significantly higher than those in IM group. Dynamic monitoring of virological, immunological, and inflammatory indicators in HLH patients during treatment showed that EBV DNA gradually decreased in patients with good prognosis. Inflammatory indicators significantly decreased and returned to normal, lymphocyte count significantly increased and returned to normal during treatment. However, patients with poor prognosis showed rebound increase in EBV DNA and inflammatory indicators in the later stage of treatment, while lymphocyte count further decreased with the recurrence of the disease. CONCLUSIONS: Exhausted and damaged immune function in host by persistent stimulation of EB viral antigen is one of the main pathogeneses of EB-HLH. Lymphocyte count and serum ferritin level are effective indicators to monitor the therapeutic efficacy during the treatment to HLH.
Sujet(s)
Infections à virus Epstein-Barr , Herpèsvirus humain de type 4 , Mononucléose infectieuse , Lymphohistiocytose hémophagocytaire , Humains , Enfant , Mâle , Femelle , Enfant d'âge préscolaire , Herpèsvirus humain de type 4/immunologie , Lymphohistiocytose hémophagocytaire/immunologie , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/sang , Mononucléose infectieuse/immunologie , Mononucléose infectieuse/sang , Mononucléose infectieuse/virologie , Mononucléose infectieuse/diagnostic , Infections à virus Epstein-Barr/immunologie , Infections à virus Epstein-Barr/virologie , Infections à virus Epstein-Barr/sang , ADN viral/sang , Inflammation/immunologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Charge virale , Ferritines/sang , Numération des lymphocytes , Adolescent , Nourrisson , Sous-populations de lymphocytes/immunologieRÉSUMÉ
The clinical data of five patients [one male and four female; median age: 31 (21-65) years] with cytomegalovirus (CMV)-induced hemophagocytic lymphohistiocytosis (HLH) diagnosed and treated in the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed from January 2011 to December 2020. None of the patients had any underlying disease, and all were immunocompetent. The main clinical presentations were fever in all five patients, splenomegaly in four, enlarged lymph nodes in two, liver enlargement in one, and rash in three. Pulmonary infection was found in three patients, two of whom developed respiratory failure. Two patients had jaundice. Central nervous system symptoms and gastrointestinal bleeding were observed in one case. All patients received glucocorticoids and antiviral therapy. One patient was treated with the COP (cyclophosphamide+vincristine+prednisone) chemotherapy regimen after antiviral therapy failed and he developed central nervous system symptoms. After treatment, four patients achieved remission, but the fifth pregnant patient eventually died of disease progression after delivery. CMV-associated HLH in an immunocompetent individual without underlying diseases is extremely rare, and most patients have favorable prognosis. Antiviral therapy is the cornerstone of CMV-HLH treatment.
Sujet(s)
Antiviraux , Infections à cytomégalovirus , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/traitement médicamenteux , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/étiologie , Mâle , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/diagnostic , Femelle , Adulte , Études rétrospectives , Adulte d'âge moyen , Antiviraux/usage thérapeutique , Jeune adulte , Sujet âgé , Cytomegalovirus , PronosticRÉSUMÉ
Objective: Epstein-Barr virus (EBV) is a common virus that infects a large portion of the world's population, with most people becoming infected during childhood or adolescence. The objective of this article is to analyze the clinical and laboratory examination results of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in children, summarize its characteristics, identify critically ill children as soon as possible, and provide a basis for diagnosis and treatment. Method: The retrospective analysis in this study involved collecting data from 34 cases of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) admitted to Hebei Children's Hospital from January 2019 to December 2022. The inclusion criteria for the cases studied likely included confirmed diagnosis of EBV-HLH based on clinical symptoms, laboratory findings, and possibly viral testing results. Key parameters analyzed in the study may have included clinical manifestations, laboratory test results (e.g., levels of lactate dehydrogenase, sCD25, IL-10, calcium ions, glutathione aminotransferase, ferritin, alanine aminotransferase, D-dimer), survival rates, and other relevant indicators. Additionally, the cases were likely divided into high-risk groups (with multiple organ dysfunction or requiring ventilator-assisted ventilation) and non-risk groups for comparative analysis. Results: The results showed that 34 cases (100%) of EBV-HLH had elevated levels of lactate dehydrogenase, sCD25, IL-10, and decreased levels of calcium ions. 97.1% of the children had a fever and elevated levels of glutathione aminotransferase and ferritin, with an 8-week survival rate of 91.2%. The levels of alanine aminotransferase, alanine aminotransferase, lactate dehydrogenase, ferritin, D-dimer, and sCD25 in critically ill children were significantly higher than those in the non-critically ill group, with statistical significance (P < .05). The decreased levels of calcium ions in EBV-HLH patients suggest potential tissue damage and disruption of calcium homeostasis, contributing to the systemic manifestations of the disease. Compared with non-critical recombinant albumin, the decrease in critical recombinant albumin was statistically significant (P < .05). Conclusion: Significant changes in laboratory results can contribute to the early diagnosis and targeted treatment of EBV-HLH, especially for critically ill children. We should pay timely attention to laboratory examinations, diagnosis and treatment, and avoid or reduce the occurrence of adverse consequences. Based on the results of the study on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in children, specific strategies and criteria can be proposed to aid in the early identification of critically ill children with this condition in clinical practice: Clinical Screening, Risk Stratification, Early Intervention, Multidisciplinary Management and Educational Measures.
Sujet(s)
Infections à virus Epstein-Barr , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/sang , Femelle , Mâle , Études rétrospectives , Enfant , Enfant d'âge préscolaire , Infections à virus Epstein-Barr/complications , Nourrisson , Herpèsvirus humain de type 4 , AdolescentRÉSUMÉ
OBJECTIVE: Monitoring the disease status of Epstein-Barr virus (EBV)-related hemophagocytic lymphohistiocytosis (HLH) patients is crucial. This study aimed to investigate the different strategies and outcomes of patients with EBV-HLH and re-elevated EBV-DNA. METHOD: A retrospective analysis was conducted on 20 patients diagnosed with EBV-HLH. Clinical features, laboratory tests, treatments, plasma EBV-DNA levels, and outcomes were assessed. Three cases were highlighted for detailed analysis. RESULTS: Nine of the 20 patients had a re-elevation of EBV-DNA during treatment, and 55.5 % (5/9) experienced relapses. Patients with persistently positive plasma EBV-DNA (n = 4) and those with re-elevated EBV-DNA after conversion (n = 9) showed a significantly higher relapse rate compared to those with persistently negative EBV-HLH (n = 7) (p < 0.05). Among the highlighted cases, Case 1 exhibited plasma EBV-DNA re-elevation after four weeks of treatment without relapse, maintaining stability with the original treatment regimen, and eventually, his plasma EBV-DNA turned negative. In Case 2, plasma EBV-DNA was elevated again with a recurrence of HLH after L-DEP. Consequently, she underwent allogeneic hematopoietic stem cell transplantation and eventually achieved complete remission (CR) with negative plasma EBV-DNA. Case 3 experienced plasma EBV-DNA re-elevation after L-DEP but remained in CR, discontinuing chemotherapy without relapse. CONCLUSION: The re-elevation of plasma EBV-DNA during EBV-HLH treatment poses challenges in determining disease status and treatment strategies. Optimal management decisions require a combination of the level of elevated EBV-DNA, the intensity of hyperinflammation, and the patient's immune function.
Sujet(s)
ADN viral , Infections à virus Epstein-Barr , Herpèsvirus humain de type 4 , Lymphohistiocytose hémophagocytaire , Récidive , Humains , Lymphohistiocytose hémophagocytaire/thérapie , Lymphohistiocytose hémophagocytaire/sang , Lymphohistiocytose hémophagocytaire/virologie , Études rétrospectives , Mâle , Infections à virus Epstein-Barr/sang , Infections à virus Epstein-Barr/complications , Infections à virus Epstein-Barr/thérapie , Femelle , ADN viral/sang , Enfant d'âge préscolaire , Enfant , Herpèsvirus humain de type 4/génétique , Herpèsvirus humain de type 4/isolement et purification , Nourrisson , Adolescent , Résultat thérapeutique , Pertinence cliniqueSujet(s)
Infections humaines à adénovirus , Adénovirus humains , Colite , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/diagnostic , Femelle , Colite/virologie , Enfant , Adénovirus humains/isolement et purification , Infections humaines à adénovirus/diagnostic , Infections humaines à adénovirus/complications , Infections humaines à adénovirus/virologieSujet(s)
Herpèsvirus humain de type 8 , Lymphohistiocytose hémophagocytaire , Sarcome de Kaposi , Humains , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/virologie , Diagnostic différentiel , Sarcome de Kaposi/diagnostic , Sarcome de Kaposi/virologie , Herpèsvirus humain de type 8/isolement et purification , Mâle , Syndrome de libération de cytokines/diagnostic , Adulte d'âge moyenRÉSUMÉ
Hemophagocytic lymphohistiocytosis is a severe hyperinflammatory syndrome that can be potentially life-threatening without appropriate treatment. Although viral infection is the most common trigger of hemophagocytic lymphohistiocytosis, cases of herpes simplex virus type 1-induced hemophagocytic lymphohistiocytosis are rare in adults. This study aims to provide a comprehensive overview of the clinical characteristics and treatment outcomes associated with HSV-1-induced HLH. We herein report an adult case of hemophagocytic lymphohistiocytosis caused by herpes simplex virus type 1, diagnosed on the basis of peripheral blood metagenomic next-generation sequencing results. The patient exhibited a favorable response to treatment, involving dexamethasone, intravenous immunoglobulin, and acyclovir. Notably, etoposide administration was deemed unnecessary, and there has been no recurrence of the disease within the year following treatment. Early and sensitive recognition, rapid and precise diagnosis, and timely and appropriate treatment facilitated the successful treatment of this case.
Sujet(s)
Herpès , Herpèsvirus humain de type 1 , Lymphohistiocytose hémophagocytaire , Humains , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/virologie , Lymphohistiocytose hémophagocytaire/traitement médicamenteux , Herpèsvirus humain de type 1/isolement et purification , Herpèsvirus humain de type 1/génétique , Herpès/diagnostic , Herpès/traitement médicamenteux , Herpès/virologie , Herpès/complications , Mâle , Adulte , Dexaméthasone/usage thérapeutique , Dexaméthasone/administration et posologie , Aciclovir/usage thérapeutique , Aciclovir/administration et posologie , Antiviraux/usage thérapeutiqueRÉSUMÉ
Hepatic manifestations of Epstein-Barr virus (EBV) infection are relatively common, mild, and self-limiting. Although fulminant hepatic failure has been reported in a few cases, the contributing factors are unclear. This report discusses a pediatric case of EBV-associated acute liver failure that required urgent liver transplantation; however, liver damage continued to progress post-liver replacement. Monoclonal CD8+ T cells that preferentially infiltrated the native and transplanted liver were positive for EBV-encoded small RNA, suggesting a pathophysiology similar to that of EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Therefore, subsequent chemotherapy and hematopoietic cell transplantation was conducted, which led to cure. This is the first case of EBV-associated acute liver failure that relapsed post-liver transplant. As such, it sheds light on an under-recognized clinical entity: liver-restricted hyperinflammation caused by EBV-infected monoclonal CD8+ T cells. This phenomenon needs to be recognized and differentiated from hepatitis/hepatic failure caused by EBV-infected B cells, which has a relatively benign clinical course.
Sujet(s)
Lymphocytes T CD8+/virologie , Infections à virus Epstein-Barr/virologie , Herpèsvirus humain de type 4/génétique , Défaillance hépatique aigüe/virologie , Foie/anatomopathologie , Lymphohistiocytose hémophagocytaire/virologie , Enfant d'âge préscolaire , Infections à virus Epstein-Barr/immunologie , Transplantation de cellules souches hématopoïétiques , Humains , Foie/imagerie diagnostique , Défaillance hépatique aigüe/thérapie , Transplantation hépatique , Lymphohistiocytose hémophagocytaire/thérapie , Mâle , Tomographie par émission de positons couplée à la tomodensitométrie , ARN viral/analyse , Résultat thérapeutiqueSujet(s)
Virus Hantaan/pathogénicité , Fièvre hémorragique avec syndrome rénal/diagnostic , Réaction leucémoïde/virologie , Lymphohistiocytose hémophagocytaire/virologie , Moelle osseuse/anatomopathologie , Fièvre hémorragique avec syndrome rénal/complications , Humains , Réaction leucémoïde/complications , Lymphohistiocytose hémophagocytaire/complications , Mâle , Adulte d'âge moyenRÉSUMÉ
Hemophagocytic lymphohistiocytosis (HLH) is a multisystem disease wherein there is an exaggerated immune system activation following a trigger such as infection, malignancy, or autoimmune diseases. Here we report a case of a 3-year-old boy who presented to us with fever, was diagnosed with dengue fever, and treatment started for the same. Clinical response was poor to treatment and high-grade fever persisted. Subsequent evaluation showed Plasmodium falciparum malaria and treatment was initiated with antimalarial drugs. Further clinical deterioration with poor trend of laboratory values over the next few days prompted evaluation for HLH; workup was positive satisfying the HLH-2004 criteria and IV dexamethasone was started. The child gradually improved and was discharged with normal counts on follow-up over the next 3 months. This article emphasizes on the importance of high degree of suspicion, early workup, and initiation of treatment for HLH for a better outcome.
Sujet(s)
Virus de la dengue/métabolisme , Dengue , Lymphohistiocytose hémophagocytaire , Paludisme à Plasmodium falciparum , Plasmodium falciparum/métabolisme , Enfant d'âge préscolaire , Dengue/sang , Dengue/diagnostic , Dengue/thérapie , Humains , Lymphohistiocytose hémophagocytaire/sang , Lymphohistiocytose hémophagocytaire/parasitologie , Lymphohistiocytose hémophagocytaire/thérapie , Lymphohistiocytose hémophagocytaire/virologie , Paludisme à Plasmodium falciparum/sang , Paludisme à Plasmodium falciparum/diagnostic , Paludisme à Plasmodium falciparum/thérapie , MâleRÉSUMÉ
BACKGROUND: For a patient presenting with fever, multiple lymphadenopathy and splenomegaly, pathogen infection should be preferentially considered, followed by lymphoid malignancies. When traditional laboratory and pathological detection cannot find the pathogenic microorganism, metagenomic sequencing (MGS) which targets the person's genome for exceptional genetic disorders may detect a rare pathogen. CASE PRESENTATION: Here, we introduced the diagnostic clue of a case of multicentric Castleman disease (MCD) with hemophagocytic syndrome which was elicited from the detection of human herpesvirus-8 in the blood of a HIV-1 infected person by MGS technology during pathogen inspection. This case highlights the need to increase the awareness of MCD among clinicians and pathologists. CONCLUSIONS: MGS technology may play a pivotal role in providing diagnostic clues during pathogen inspection, especially when pathogens are not detectable by conventional methods.
Sujet(s)
Hyperplasie lymphoïde angiofolliculaire/anatomopathologie , Infections à Herpesviridae/complications , Herpèsvirus humain de type 8/isolement et purification , Lymphohistiocytose hémophagocytaire/anatomopathologie , Hyperplasie lymphoïde angiofolliculaire/étiologie , Hyperplasie lymphoïde angiofolliculaire/virologie , Infections à Herpesviridae/virologie , Humains , Lymphohistiocytose hémophagocytaire/étiologie , Lymphohistiocytose hémophagocytaire/virologie , Mâle , Adulte d'âge moyen , PronosticRÉSUMÉ
BACKGROUND: Systemic Epstein-Barr virus+ T-cell lymphoma (sEBV+ TCL) occurs in childhood and young adults, and is exceptionally rare in older adults. METHODS: We investigated clinicopathological features in 16 patients of various ages with systemic EBV+ CD8+ T-lymphoproliferative diseases. RESULTS: Eight younger patients and four of eight older adults had sEBV+ CD8+ TCL, with invasion by medium-sized to/or large atypical lymphocytes primarily in bone marrow and lymph nodes, hemophagocytic lymphohistiocytosis (HLH), and progressive clinicopathological course. A further two patients demonstrated EBV+ node-based CD8+ large TCL without HLH, while the remaining two had the systemic form of chronic active EBV infection (sCAEBV) with CD8+ small lymphocytes. Past history of sCAEBV-like lesions was observed in one sEBV+ TCL patient (8.3%). Immunohistologically, in 12 sEBV+ TCL patients, atypical lymphocytes were positive for phosphate signal transducer and activator of transcription 3 (66.7%), CMYC (83.3%), and p53 (75%). Strong reactions of programmed cell death-ligand (PD-L)1+ tumor or non-neoplastic cells were detected in nine sEBV+ TCL patients (75%). Clonal peaks of the T-cell receptor (TCR) γ gene were detected in eight sEBV+ TCL patients by polymerase chain reaction. Four younger patients in sEBV+ TCL (33.3%) are in remission with chemotherapies including etoposide, and three of the four underwent allogeneic stem cell transplantation (SCT). CONCLUSION: sEBV+ CD8+ TCL was observed in younger and older adults with less history of sCAEBV. HLH, tumor cell atypia, immunohistological findings, and progressive clinical course were characteristic of sEBV+ CD8+ TCL. Prompt chemotherapy and SCT induced tumor regression in sEBV+ CD8+ TCL patients.
Sujet(s)
Lymphocytes T CD8+/anatomopathologie , Prolifération cellulaire , Infections à virus Epstein-Barr/anatomopathologie , Herpèsvirus humain de type 4/pathogénicité , Lymphohistiocytose hémophagocytaire/anatomopathologie , Lymphome T/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antinéoplasiques/usage thérapeutique , Marqueurs biologiques tumoraux/analyse , Lymphocytes T CD8+/immunologie , Lymphocytes T CD8+/virologie , Transformation cellulaire virale , Enfant d'âge préscolaire , Infections à virus Epstein-Barr/immunologie , Infections à virus Epstein-Barr/thérapie , Infections à virus Epstein-Barr/virologie , Femelle , Interactions hôte-pathogène , Humains , Lymphohistiocytose hémophagocytaire/immunologie , Lymphohistiocytose hémophagocytaire/thérapie , Lymphohistiocytose hémophagocytaire/virologie , Lymphome T/immunologie , Lymphome T/thérapie , Lymphome T/virologie , Mâle , Adulte d'âge moyen , Induction de rémission , Études rétrospectives , Transplantation de cellules souches , Résultat thérapeutique , Jeune adulteRÉSUMÉ
OBJECTIVE: Cytokine storms are central to the development of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Previous studies have shown that single-nucleotide polymorphisms (SNPs) of cytokine genes may be associated with the development of EBV-HLH in children. As such, we investigated the association between susceptibility to EBV-HLH in children and SNPs and haplotypes of genes encoding interleukin-2 receptor subunit alpha (IL2RA), interleukin-10 (IL10), interferon gamma (IFNG), interferon regulatory factor 5 (IRF5), and C-C chemokine receptor 2 (CCR2). METHODS: Sixty-six children with EBV-HLH and 58 healthy EBV-seropositive controls were enrolled in this study. SNPs of IL2RA rs2104286, rs12722489, and rs11594656; IL10 rs1800896, rs1800871, and rs1800872; IFNG rs2430561, IRF5 rs2004640, and CCR2 rs1799864 were assayed and genotyped using the SNaPshot technique. RESULTS: Frequencies of the A allele of IL2RA rs2104286 and IL10 rs1800896, and C allele of IL-10 rs1800872 were significantly higher in the EBV-HLH group than in the control group. The AA genotype of IL2RA rs2104286 and IL10 rs1800896, and the CC genotype of IL10 rs1800872 might be associated with a significantly high risk of EBV-HLH. However, the frequencies of genotypes and alleles of IL2RA rs2104286, IL10 rs1800871, IFNG rs2430561, IRF5 rs2004640, and CCR2 rs1799864 were similar in both groups. Additionally, IL2RA AGT (rs2104286-rs12722489-rs11594656) and IL10 ACC (rs1800896-rs1800871-rs1800872) haplotypes were also associated with an increased risk of EBV-HLH. CONCLUSIONS: SNPs of IL2RA rs2104286, IL10 rs1800896 and rs1800872 and the haplotypes of IL2RA AGT and IL10 ACC were highly associated with susceptibility to EBV-HLH in children.